vimarsana.com
Home
Live Updates
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial o
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial o
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Related Keywords
United States ,
Russia ,
Ukraine ,
America ,
Paula Schwartz ,
Andreas Muehler ,
Jessica Breu ,
Daniel Vitt ,
Edna Kaplan ,
Exchange Commission ,
Rx Communications Group ,
Nasdaq ,
Immunic Inc Nasdaq ,
Immunic Inc ,
Unblinded Interim Biomarker Analysis Expected ,
Full Data Readout Expected ,
Chief Executive Officer ,
Chief Medical Officer ,
North America ,
Eastern Europe ,
Vidofludimus Calcium ,
Private Securities Litigation Reform Act ,
Annual Report ,
Investor Relations ,
Immunic ,
Nc ,